Mirum Pharmaceuticals (MIRM) vs Summit Therapeutics (SMMT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Mirum Pharmaceuticals (MIRM) has outperformed Summit Therapeutics (SMMT) over the past year, gaining 16.5% versus a loss of 22.3%. Over five years, MIRM leads with a +402.4% price change compared with +241.6% for SMMT. Summit Therapeutics is the larger company by market cap ($14.03 billion vs $5.58 billion), about 2.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MIRM | SMMT |
|---|---|---|
| Share price | $86.01 | $17.59 |
| Market cap | $5.58B | $14.03B |
| 1-day change | +5.73% | +2.45% |
| YTD return | +8.89% | +0.57% |
| 1-year return | +16.51% | -22.34% |
| 5-year return | +402.39% | +241.55% |
| EPS (TTM) | $-14.10 | $-1.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $521.31M | — |
| Revenue growth (YoY) | +54.74% | — |
| Net income (latest FY) | $-23.36M | $-1.08B |
| Operating margin | -4.25% | — |
| Net margin | -4.48% | — |
| 52-week high | $130.00 | $29.23 |
| 52-week low | $63.23 | $12.07 |
| Distance from 52-week high | -33.84% | -39.82% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +69.50% | +69.30% |
| Average volume | 705.14K | 5.87M |
| Shares outstanding | 64.93M | 797.75M |
| Employees | 433 | 265 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Summit Therapeutics is about 2.5 times larger than Mirum Pharmaceuticals by market value ($14.03B vs $5.58B).
- MIRM has outperformed SMMT by 38.9 percentage points over the past year.
About Mirum Pharmaceuticals
MIRM stock →Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 433 employees
About Summit Therapeutics
SMMT stock →Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC).
Health Care · Biotechnology: Pharmaceutical Preparations · 265 employees
MIRM vs SMMT FAQ
Which is bigger, Mirum Pharmaceuticals or Summit Therapeutics?
Summit Therapeutics (SMMT) is larger, with a market capitalization of $14.03B compared with $5.58B for Mirum Pharmaceuticals (MIRM).
Which stock has performed better over the past year, MIRM or SMMT?
MIRM returned +16.51% over the past 12 months, compared with -22.34% for SMMT (price return, excluding dividends). Past performance does not predict future results.
Are Mirum Pharmaceuticals and Summit Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.